American College of Clinical Pharmacy
      Search      Cart

Thinning the Evidence: Practical Updates for Antiplatelet and Anticoagulant Therapy

Tuesday, October 29, 2019 from 10:15 AM to 11:45 AM EDT at 3rd Floor: Trianon Ballroom

Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-19-168-L01-P
Activity Type: An Application-Based Activity

  • Dustin D. Spencer, Pharm.D., MBA, BCPSModerator: Dustin D. Spencer, Pharm.D., MBA, BCPS
    Clinical Director, Cardiopulmonary Diseases, Innovative Delivery Solutions, Cardinal Health, Houston, Texas
      View Biography

Antiplatelet Therapy for Acute Coronary Syndromes: Refining Optimal Use from Practical Experience
10:15 AM

  • Joel C. Marrs, Pharm.D., MPH, BCACP, BCCP, BCPS, CHC, CLSSpeaker: Joel C. Marrs, Pharm.D., MPH, BCACP, BCCP, BCPS, CHC, CLS
    Associate Professor, University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy & Pharmaceutical Sciences, Aurora, Colorado
      View Biography

Learning Objectives
1. Discuss the impact of opiates on delayed absorption of oral antiplatelet agents and recommend necessary treatment modifications to maximize antiplatelet effect.
2. Describe the current place in therapy for cangrelor by reviewing clinical trial data and accumulating post-marketing experience.
3. Examine evidence for switching oral P2Y12 receptor inhibitor therapy after initial treatment and describe the most appropriate method to switch therapy for a given clinical scenario.
4. Formulate patient-specific antiplatelet treatment recommendations including agent choice and optimal duration considering indication, risk for thrombosis and bleeding, and other comorbidities.
Directing the Course: Update on Oral Anticoagulation Post-ACS
11:00 AM

  • Shannon W. Finks, Pharm.D., FCCP, BCPS, BCCP, AHSCP-CHCSpeaker: Shannon W. Finks, Pharm.D., FCCP, BCPS, BCCP, AHSCP-CHC
    Professor of Clinical Pharmacy University of Tennessee College of Pharmacy Memphis, Tennessee
      View Biography

Learning Objectives
1. Evaluate current evidence to tailor anticoagulation post-acute coronary syndrome for patients requiring triple-therapy.
2. Discuss the use of low dose direct oral anticoagulants (DOACs) post-acute coronary syndrome.
3. Review the recent data on bleeding rates with the combination use of DOACs and dual antiplatelet therapy (DAPT).